

1 **SARS-CoV-2 Viral Genes Compromise Survival and Functions of Human**
2 **Pluripotent Stem Cell-derived Cardiomyocytes via Reducing Cellular ATP Level**

3

4 **Authors**

5 Juli Liu¹, Yucheng Zhang^{2,3}, Shiyong Wu¹, Lei Han¹, Cheng Wang¹, Sheng Liu², Ed
6 Simpson^{2,3}, Ying Liu¹, Yue Wang², Weinian Shou¹, Yunlong Liu^{2,3}, Michael Rubart-von
7 der Lohe¹, Jun Wan^{2,3}, Lei Yang^{1,3,*}

8

9 **Affiliations**

10 ¹ Department of Pediatrics, Indiana University School of Medicine, Herman B Wells
11 Center for Pediatric Research, Indianapolis, IN 46202, USA

12 ² Department of Medical and Molecular Genetics, Indiana University School of Medicine,
13 Indianapolis, IN 46202, USA

14 ³ Center for Computational Biology and Bioinformatics, Indiana University School of
15 Medicine, Indianapolis, IN 46202, USA

16

17 *Correspondence: lyang7@iu.edu

18

19 **Keywords:** COVID-19, SARS-CoV-2, apoptosis, cardiac dysfunction, cardiomyocyte,
20 human pluripotent stem cell

21

22 **Abstract**

23 Cardiac manifestations are commonly observed in COVID-19 patients and prominently
24 contributed to overall mortality. Human myocardium could be infected by SARS-CoV-2,
25 and human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) are susceptible to
26 SARS-CoV-2 infection. However, molecular mechanisms of SARS-CoV-2 gene-induced
27 injury and dysfunction of human CMs remain elusive. Here, we find overexpression of
28 three SARS-CoV-2 coding genes, Nsp6, Nsp8 and M, could globally compromise
29 transcriptome of hPSC-CMs. Integrated transcriptomic analyses of hPSC-CMs infected
30 by SARS-CoV-2 with hPSC-CMs of Nsp6, Nsp8 or M overexpression identified
31 concordantly activated genes enriched into apoptosis and immune/inflammation
32 responses, whereas reduced genes related to heart contraction and functions. Further,
33 Nsp6, Nsp8 or M overexpression induce prominent apoptosis and electrical dysfunctions
34 of hPSC-CMs. Global interactome analysis find Nsp6, Nsp8 and M all interact with
35 ATPase subunits, leading to significantly reduced cellular ATP level of hPSC-CMs. Finally,
36 we find two FDA-approved drugs, ivermectin and meclizine, could enhance the ATP level,
37 and ameliorate cell death and dysfunctions of hPSC-CMs overexpressing Nsp6, Nsp8 or
38 M. Overall, we uncover the global detrimental impacts of SARS-CoV-2 genes Nsp6, Nsp8
39 and M on the whole transcriptome and interactome of hPSC-CMs, define the crucial role
40 of ATP level reduced by SARS-CoV-2 genes in CM death and functional abnormalities,
41 and explore the potentially pharmaceutical approaches to ameliorate SARS-CoV-2
42 genes-induced CM injury and abnormalities.

43

44 **Abbreviations and Acronyms**

45 SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2; COVID-19, coronavirus
46 disease-2019; ACE2 angiotensin converting enzyme 2; hPSCs, human pluripotent stem cells.

47

48 **Introduction**

49 Coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory
50 syndrome coronavirus 2 (SARS-CoV-2), has unprecedentedly affected health and economy
51 world widely (1,2). Since the end of 2019, SARS-CoV-2 has infected over 339 million people
52 in the world, and in the US, SARS-CoV-2 has caused over 850,000 deaths. Although the
53 primary cause of death by SARS-CoV-2 infection is respiratory failure, cardiac complications,
54 including acute myocardial injury, myocarditis, arrhythmias and even sudden death,
55 prominently contributed to the overall SARS-CoV-2-caused mortality (3-5). Concomitant
56 cardiovascular disorders have been observed in 8-25% of overall SARS-CoV-2 infected
57 population, and particularly with a high frequency among dead patients (6). Additionally, an
58 increased mortality rate was observed in patients with pre-existing cardiovascular disorders
59 (7,8). Recent studies documented the vulnerability of human myocardium infection by SARS-
60 CoV-2, confirming that SARS-CoV-2 directly infects CMs in COVID-19 patients with
61 myocarditis (9). SARS-CoV-2 virus infects and enters human cells through binding to three
62 membrane proteins, including the Angiotensin Converting Enzyme 2 (ACE2),
63 Transmembrane Serine Protease 2 (TMPRSS2)(10,11) and Transmembrane Serine
64 Protease 4 (TMPRSS4)(12). The high affinity of SARS-CoV-2 spike (S) protein with ACE2
65 makes human organs/tissues with high level of ACE2 expression as the primary targets
66 attacked by SARS-CoV-2, such as the lung, small intestine, testis, kidney and heart (13).
67 Recently, human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) were naturally

68 utilized as an *in vitro* platform to evaluate the pathological effects of SARS-CoV-2 on human
69 heart muscle cells (14). SARS-CoV-2 infects human CMs through ACE2. SARS-CoV-2-
70 infected hPSC-CMs exhibited prominently increased cell death (15,16), fractionated
71 sarcomeres (17), abnormal electrical and mechanical functions (18) and inflammation (15),
72 which recapitulated the CM injuries in COVID-19 patients with myocarditis (9). SARS-CoV-
73 2 genome encodes up to 27 genes. Currently, the molecular mechanisms, by which SARS-
74 CoV-2 genes interact with host protein networks to influence survival and functions of human
75 CMs, still largely remain elusive.

76

77 In this study, three SARS-CoV-2 viral coding genes, Nsp6, Nsp8 and M, were
78 overexpressed in hPSCs (human ESCs and iPSCs) derived CMs. The global impacts of
79 SARS-CoV-2 viral genes on the transcriptome of hPSC-CMs were determined by whole
80 mRNA-seq. We found Nsp6, Nsp8 or M overexpression in hPSC-CMs and SARS-CoV-2
81 viral infection concordantly affected the transcriptome of hPSC-CMs, with activated
82 cellular injury and immune signaling and reduced cardiac function pathways. Nsp6, Nsp8
83 or M overexpression in hPSC-CMs prominently increased apoptosis, and compromised
84 calcium handling and electrical properties. Genome-wide interactome analysis found
85 Nsp6, Nsp8 and M could all interact with proteins of the host hPSC-CMs, particularly
86 ATPase subunits, which led to significantly reduced ATP level. Given that reduced ATP
87 level could impair intracellular Ca²⁺ signaling and contractility of CMs, we then tested
88 pharmaceutical strategies to enhance the cellular ATP levels of hPSC-CMs
89 overexpressing Nsp6, Nsp8 or M. Two FDA-approved drugs, ivermectin and meclizine,
90 significantly reduced cell death and dysfunctions of hPSC-CMs with overexpression of

91 SARS-CoV-2 genes. Overall, SARS-CoV-2 genes Nsp6, Nsp8 and M exhibited
92 detrimental effects on the whole transcriptome and interactome of hPSC-CMs, and the
93 reduced cellular ATP level plays a key role in SARS-CoV-2 genes-induced CM death and
94 abnormalities.

95

96 **Methods:**

97 A detailed methods section is in the Supplemental Appendix.

98

99 **Human Pluripotent stem cell culture and differentiation**

100 Human embryonic stem cell (hESC) line H9 and human induced pluripotent stem cell
101 (hiPSC) line S3 were cultured on Matrigel (BD Biosciences)-coated plates in mTesR1
102 medium (19,20). For cardiomyocyte differentiation, cells were differentiated by following
103 a published protocol (21) with minor modification.

104

105 **Lentivirus production and cell transduction**

106 The lentiviral vectors pLVX-EF1alpha-IRES-Puro-2xStreg-SARS-CoV-2 (Nsp6, Nsp8, M)
107 (Addgene plasmids #141395, #141372, #141374) were transfected into the HEK293T
108 cells with packaging plasmids. After 48 hrs, viral supernatant was collected. H9 hESCs
109 or S3 hiPSCs cultured in mTesR1 medium were incubated with viral media for 4 hrs.
110 Same infection was repeated after 24 hrs. Puromycin was added to select puromycin-
111 resistant H9 hESCs and S3 hiPSCs clones after 48 hrs of virus infection. Empty vector
112 infected hPSCs were used as control.

113

114 **Whole mRNA-seq**

115 Total RNA was evaluated for quantity and quality by using Agilent Bioanalyzer 2100. The
116 pooled cDNA libraries were sequenced by a NovaSeq 6000 sequencer at 300pM final
117 concentration for 100b paired-end sequencing (Illumina, Inc.). Approximately 30-40M
118 reads per library were generated. A Phred quality score (Q score) was used to measure
119 the quality of sequencing. More than 90% of the sequencing reads reached Q30 (99.9%
120 base call accuracy).

121

122 **Co-immunoprecipitation mass spectrometry (Co-IP-MS)**

123 Total cell proteins were extracted by using Pierce™ Classic Magnetic IP/Co-IP Kit
124 (Thermo Scientific, 88804, USA) according to the manuals. Protein Co-
125 immunoprecipitation (Co-IP) was performed by using Pierce™ Classic Magnetic IP/Co-
126 IP Kit as well. Co-IP protein samples analysis were performed by using Western blotting
127 or submitted to the Proteomics Core Facility at the Indiana University School of Medicine
128 (IUSM) for mass spectrometry analysis.

129

130 **Quantification and Statistical Analysis**

131 Data comparison between two groups (gene overexpression versus control) was
132 conducted using an unpaired two-tailed *t*-test. All data were presented as mean ± S.D.
133 from at least three independent experiments. Differences with *P* values less than 0.05
134 were considered significant.

135

136 **Results**

137 **Prediction of SARS-CoV-2 coding genes that potentially affect functions of human** 138 **cardiomyocytes (CMs)**

139 Myocardial injury and dysfunction are observed in patients infected by the SARS-CoV-2
140 virus(22). The 30kb SARS-CoV-2 viral genome encodes up to 14 open-reading frames
141 (Figure 1A). Currently, the host responsive mechanisms of human heart muscle cells to
142 SARS-CoV-2 viral genes still remain elusive. To predict the impact and mechanisms of
143 SARS-CoV-2 coding genes on human cardiac injuries and dysfunctions, we analyzed the
144 published datasets from a previous study(23), which comprehensively defined the
145 interactive map of all SARS-CoV-2 proteins in human HEK-293T/17 cells. Here, we only
146 focus on the SARS-CoV-2 genes, which mainly interact with proteins that are highly
147 expressed in human CMs. By overlapping the 332 high-confident SARS-CoV-2
148 interactors in the HEK-293T/17 cells with the 2198 proteins that are highly expressed in
149 the human cardiomyocytes (human protein atlas, <http://www.proteinatlas.org>), we found
150 three SARS-CoV-2 coding genes, Nsp6, M and Nsp8, could selectively interact with the
151 proteins essential for survival and function of human CMs (Figure 1B). Therefore, we
152 decided to pursue the functional studies of those three SARS-CoV-2 genes in hPSC-CMs.
153 Firstly, three human ES and iPS cell lines overexpressing M, Nsp8 and Nsp6, respectively,
154 were established by using lentivirus, followed with differentiation into contracting CMs for
155 further assessments (Figure 1C). This strategy allows uniformly high gene expression in
156 hPSC-CMs compared with the AAV9-mediated gene delivery into differentiated hPSC-
157 CMs. Since SARS-CoV-2 virus infects human cells through binding with ACE2,

158 TMPRSS2(10,11) or TMPRSS4(12), we profiled their expression dynamics during CM
159 differentiation from WT hESCs using qRT-PCR (Figure 1D). Cardiac troponin T (CTNT)
160 is a marker of CMs (Figure 1D). ACE2 was lowly expressed in hESCs, but rapidly
161 increased in hESCs-derived CMs (hESC-CMs). TMPRSS2 expression level dropped
162 during CM differentiation (Figure 1D), whereas TMPRSS4 expression exhibited a
163 fluctuant patterning (Figure 1D). Our single cell RNA-seq data from hESC-CMs (24)
164 confirmed the relatively higher expression level of ACE2 than those of TMPRSS2 and
165 TMPRSS4 in hESC-CMs (Figure 1E). Similar as hESC-CMs, adult human heart tissues
166 express higher level of ACE2 than TMPRSS2 and TMPRSS4 (Supplementary Figures
167 1A-C). Furthermore, pseudotyped SARS-CoV-2 virus could infect WT hESC-CMs (Figure
168 1F), which was consistent with recent reports of direct SARS-CoV-2 infection of hPSC-
169 CMs (15,16).

170

171 **Whole mRNA-seq reveals the global impact of SARS-CoV-2 viral genes on the** 172 **transcriptome of human cardiomyocytes**

173 Nsp6^{OE}, Nsp8^{OE} or M^{OE} and control hESCs (OE, overexpression; Figures 2A,
174 Supplementary Figure 1D) were differentiated into CMs, followed with a published
175 protocol (25) to enrich CMs till over 90% purity by adding lactate medium. Empty lenti-
176 vector infected hPSCs were used as control. Next, whole mRNA-seq was performed to
177 profile differentially expressed genes (Figure 2B). We found Nsp6^{OE}, Nsp8^{OE} or M^{OE}
178 hESC-CMs exhibited significantly changed gene expression profile when compared with
179 control CMs (Figures 2C-E, Table S1). Interestingly, gene ontology (GO) analysis showed
180 that Nsp6^{OE}, Nsp8^{OE} or M^{OE} globally affect the transcriptome of hESC-CMs, including

181 activated immune response, protein modification/ubiquitination, defense response,
182 regulation of proliferation and extracellular matrix organization etc. in hESC-CMs.
183 (Figures 2F-G, Supplementary Figures 2A-F). Moreover, in hESC-CMs, genes co-
184 upregulated by Nsp6^{OE}, Nsp8^{OE} and M^{OE} could be enriched into multiple signaling
185 pathways, including p53 signaling, fibrosis, oxidative stress response, and virus entry via
186 endocytic pathways (Figures 2H-I). These data indicated that Nsp6^{OE}, Nsp8^{OE} and M^{OE}
187 could trigger stress-related signaling pathways in human CMs. Additionally, Nsp6^{OE},
188 Nsp8^{OE} and M^{OE} differentially affected the expression of genes associated with
189 senescence, NF- κ B and STAT3 signaling pathways (Figure 2J), suggesting the diverse
190 influences of SARS-CoV-2 genes on the transcriptome of host hESC-CMs.

191

192 Next, we compared the transcriptomic alternations due to these three individual SARS-
193 CoV-2 proteins with gene expression changes of the hiPSC-CMs infected by the wild type
194 SARS-CoV-2 virus from a previously published mRNA-seq dataset (Sharma *et al.*, 2020)
195 (Figure 3A). We found that both up- and down-regulated DEGs caused by SARS-CoV-2
196 infection were significantly enriched in DEGs by Nsp6^{OE}, Nsp8^{OE} and M^{OE} (Figure 3B-C),
197 which were enriched in apoptosis, inflammation/immune and heart contraction pathways.
198 Together, Nsp6^{OE}, Nsp8^{OE} and M^{OE} and SARS-CoV-2 infection globally influenced the
199 transcriptome of hPSC-CMs by activating cellular injury responses, and affecting CM
200 functions, suggest the important role of these three SARS-CoV-2 genes in SARS-CoV-2
201 infection-caused CM injuries. Interestingly, ~70% of DEGs in SARS-CoV-2-infected
202 hiPSC-CMs were not prominent in individual Nsp6^{OE}, Nsp8^{OE} and M^{OE} hiPSCs (Figure
203 3G-H, grey areas), which were enriched into cellular metabolism, regulation of

204 transcription, apoptosis (Figure 3I), and ATP/fatty acid/amino acid metabolic process
205 (Figure 3J). These significant differences at transcriptomic level indicate that other SARS-
206 CoV-2 genes, except Nsp6/Nsp8/M, could also differentially affect the transcriptome of
207 host hiPSC-CMs, likely via targeting different genes or pathways.

208

209 **SARS-CoV-2 genes induce cell death in hPSC-derived cardiomyocytes**

210 The whole mRNA-seq results indicated that overexpression of SARS-CoV-2 viral genes
211 could increase expressions of cell death/apoptosis associated genes in hESC-CMs.
212 Therefore, we next assessed apoptosis of hESC-CMs. Firstly, Nsp6^{OE}, Nsp8^{OE}, M^{OE} and
213 control hESCs were differentiated into CMs using a 2D monolayer differentiation
214 method(21,24) (Figure 4A). After 12 days' CM differentiation, flow cytometry was
215 conducted to detect the ratios of TUNEL⁺ cells in the CTNT⁺ hESC-CMs. We found
216 significantly increased ratios of TUNEL⁺ cells in the Nsp6^{OE}, Nsp8^{OE} and M^{OE} hESC-CMs
217 when compared with control hESC-CMs (Figures 4B-C). Immunofluorescent staining on
218 the 2D cultured hESC-CMs also found increased percentages of TUNEL⁺ cells in Nsp6^{OE},
219 Nsp8^{OE} and M^{OE} hESC-CMs compared to that of control hESC-CMs (Figures 4D-E).
220 Since hESC-CMs were dissociated into single cells for flow cytometry analysis, some
221 late-stage apoptotic cells tended to be broken during dissociation, the flow cytometry
222 quantification of apoptotic cells gave rise to a lower percentage value than that by
223 immunostaining. To further confirm the results of TUNEL assay, we quantified the ratios
224 of Annexin V⁺ CMs and observed increased ratios of Annexin V⁺ CMs in Nsp6^{OE}, Nsp8^{OE}
225 or M^{OE} hESC-CMs compared to control hESC-CMs (Figures 4F-G). Annexin V has a
226 strong affinity for phosphatidylserine (PS) residues on the surface of the cell that is an

227 early marker of apoptosis. Finally, we quantified the ratios of cleaved-CASP3⁺ CMs
228 (Supplementary Figure 3). Cleaved-CASP3 is an activation form of Caspase-3
229 responsible for apoptosis execution. Increased percentages of cleaved-CASP3⁺ CMs
230 were found in Nsp6^{OE}, Nsp8^{OE} or M^{OE} hESC-CMs when compared with control hESC-
231 CMs, shown by the data from flow cytometry (Supplementary Figure 3A) and
232 immunostaining (Supplementary Figures 3B-C). Together, these results demonstrate that
233 Nsp6^{OE}, Nsp8^{OE} and M^{OE} could induce significant cell death of hESC-CMs under the 2D
234 culture condition.

235 Next, in order to recapitulate human myocardium-like tissues, 3D beating embryoid
236 bodies (EBs) were differentiated from hiPSCs by using our established differentiation
237 system (26,27) (Figure 4H). Prominently increased percentages of TUNEL⁺ CMs were
238 found in Nsp6^{OE}, Nsp8^{OE} or M^{OE} hiPSC-derived 3D EBs when compared to control hiPSC-
239 EBs by using flow cytometry and immunofluorescent staining (Figures 4I-L), which were
240 similar with the results from 2D condition-derived CMs. Lastly, the protein levels of
241 apoptotic markers, cleaved-CASP3 and cleaved-CASP9, significantly increased in
242 hiPSC/hESC-EBs with Nsp6^{OE}, Nsp8^{OE} or M^{OE} when compared with control EBs (Figures
243 4M-N). All these results demonstrate that overexpression of SARS-CoV-2 genes can
244 induce cell death of hPSC-CMs.

245

246 **Co-IP Mass Spectrometry (MS) reveals the interactive protein networks of hPSC-**
247 **CMs with SARS-CoV-2 genes**

248 Strep-tagged SARS-CoV-2 genes and GFP³¹ allowed pull down of all interactive proteins
249 in the host cells. We performed Co-IP MS to capture and identify the interactome of Nsp6,
250 Nsp8 or M in hESC-CMs, respectively (Figure 5A). The complete list of all interactors
251 with Nsp6, Nsp8 or M proteins in hESC-CMs could be found in the Supplementary Table
252 S2. Gene Ontology (GO) analyses of the pulled down proteins revealed that Nsp6, Nsp8
253 and M could all interact with protein factors associated with immune response, viral
254 process, and vesicle-mediated transport events (Figures 5B-D), which was in agreement
255 with a recent report in human HEK293T cells (28). Nsp6, Nsp8 and M could also interact
256 with proteins involved in cellular metabolic processes, such as ATP biosynthesis and
257 cellular biosynthetic process (Figures 5B-D), indicating that SARS-CoV-2 might impair
258 the energy supply of human CMs. Canonical signaling pathway enrichment analyses
259 found that Nsp6, Nsp8 and M could all interact with protein factors associated with cell
260 injury signaling, such as coronavirus pathogenesis pathway, viral exit from host cells,
261 calcium and cardiac hypertrophy signaling (Figures 5E-G), suggesting that SARS-CoV-2
262 infection could induce comprehensive cellular injuries and cardiomyopathy in human CMs.
263 Importantly, by zooming in the protein-protein interaction map and GO enrichment
264 analyses, we found Nsp6, Nsp8 and M interactors were associated with cardiac
265 hypertrophy and mitochondrial dysfunction (Figure 5H), and Nsp8 (Figure 5I) and M
266 (Figure 5J) interactors were functionally related to cardiac arrhythmia. Importantly, Nsp6,
267 Nsp8 or M all interacted with ATPase subunits ATP5A1 and ATP5B in hESC-CMs (Figure
268 5K), which was further validated by Co-IP Western-blotting assay in the Figure 5L. All
269 these data strongly suggest that Nsp6, Nsp8 and M could likely impair ATP biosynthesis
270 in hPSC-CMs. To confirm it, we quantified the cellular ATP levels in hESC-CMs and

271 hiPSC-CMs. As shown in the Figures 5M-N, Nsp6^{OE}, Nsp8^{OE} and M^{OE} in hESC-CMs and
272 hiPSC-CMs could prominently reduce the ATP levels when compared to control CMs. All
273 these data demonstrate the detrimental role of Nsp6, Nsp8 and M interactomes in hPSC-
274 CMs, which lead to impaired ATP homeostasis of hPSC-CMs.

275

276 **FDA-approved drugs ivermectin and meclizine ameliorate apoptosis of the Nsp6^{OE},**
277 **Nsp8^{OE} or M^{OE} hPSC-CMs**

278 Nsp6^{OE}, Nsp8^{OE} or M^{OE} reduced ATP level of hPSC-CMs, and decreased ATP level has
279 been found to cause apoptosis in various cell types including CMs (29-32). Therefore, we
280 posited that pharmaceutical chemical, which functions to enhance cellular ATP
281 biosynthesis, could potentially reduce apoptosis of Nsp6^{OE}, Nsp8^{OE} or M^{OE} hESC-CMs.
282 Two U.S. Food and Drug Administration (FDA)-approved drugs, ivermectin (antiparasitic)
283 and meclizine (antiemetic), were previously reported to protect mitochondrial function and
284 maintain cellular ATP level (33-35). Interestingly, after adding ivermectin (0.5 μ M) or
285 meclizine (0.5 μ M) into culture media for 3 hrs, the ATP levels in Nsp6^{OE}, Nsp8^{OE} and
286 M^{OE} hESC-CMs significantly increased compared to the control groups without treatment
287 (Figure 6A). Notably, after 48 hrs of treatment with ivermectin (0.5 μ M) or meclizine (0.5
288 μ M), the ratios of TUNEL⁺ CMs in Nsp6^{OE}, Nsp8^{OE} and M^{OE} hiPSC-EBs were significantly
289 decreased compared with control hiPSC-EBs without drug treatment (Figures 6B-F). All
290 these results demonstrate that reduced cellular ATP level is, at least in part, the cause of
291 apoptosis induced by SARS-CoV-2 genes, and FDA-approved drugs ivermectin and
292 meclizine could ameliorate apoptosis of hPSC-CMs via restoring the cellular ATP level.

293

294 **Ivermectin and meclizine mitigate SARS-CoV-2 genes-induced abnormal calcium**
295 **handling and electrical dysfunctions of hPSC-CMs**

296 ATP Homeostasis plays an essential role in heart function. Insufficient ATP level could
297 impair intracellular Ca^{2+} signaling and excitation-contraction coupling of CMs to
298 compromise contractile capacity(36-38). We measured $[\text{Ca}^{2+}]_i$ transients in the
299 spontaneously beating Nsp6^{OE}, Nsp8^{OE} or M^{OE} hESC-CMs by using a microfluorimetry.
300 Representative time plots of changes in $[\text{Ca}^{2+}]_i$ were shown in the Figures 7A-B. While
301 control hESC-CMs exhibited regular $[\text{Ca}^{2+}]_i$ transients of uniform amplitudes, $[\text{Ca}^{2+}]_i$
302 transients in the Nsp6^{OE}, Nsp8^{OE} or M^{OE} CMs occurred at slower and irregular rates and
303 developed the delayed aftertransients, which indicated the increased Ca^{2+} leak from
304 sarcoplasmic reticulum (SR). However, adding ivermectin (0.5 μM) or meclizine (0.5 μM)
305 for 1 hr. prominently restored the abnormal rate and rhythmicity of spontaneous $[\text{Ca}^{2+}]_i$
306 transients and abrogated aftertransients in the Nsp6^{OE}, Nsp8^{OE} or M^{OE} hESC-CMs.
307 Additionally, histograms analysis of the interspike intervals (ISIs) generated from $[\text{Ca}^{2+}]_i$
308 transient recordings revealed a larger range of variations in the ISI distribution from the
309 Nsp6^{OE}, Nsp8^{OE} or M^{OE} hESC-CMs than control hESC-CMs, which could be markedly
310 reduced following treatment with ivermectin or meclizine (Figures 7C-D).

311 Next, we performed the multiple-electrodes arrays (MEAs) to capture the field potential
312 and contractions of hESC-CMs. As shown in the Figure 7E, field potential recording from
313 control hESC-CMs revealed regular contractions, whereas Nsp6^{OE}, Nsp8^{OE} or M^{OE} hESC-
314 CMs exhibited irregular and slower beating patterns. Administration of ivermectin or
315 meclizine effectively restored beating rate and rhythmicity of Nsp6^{OE}, Nsp8^{OE} and M^{OE}

316 hESC-CMs back to a similar level as control CMs (Figure 7E). We then measured the
317 field potential duration (FPD) of beating hESC-CMs to assess CM repolarization (Figure
318 7F). Nsp6^{OE}, Nsp8^{OE} and M^{OE} hESC-CMs exhibited elongated FPDs than control hESC-
319 CMs (Figure 7G, three panels; Figure 7H). After adjustment of FPD for beating rate using
320 the Bazett's formula, the corrected FPD (FPD_c) of CMs with Nsp6^{OE} and Nsp8^{OE}, but not
321 M^{OE}, remained significantly prolonged compared to control CMs (Figure 7I), suggesting
322 that Nsp6 and Nsp8 altered repolarization properties of hESC-CMs. These MEAs results,
323 together with abnormal calcium handling, indicate that SARS-CoV-2 gene could disrupt
324 the mechanisms underlying pacemaking and repolarization of human CMs, which could
325 possibly contribute to cardiac arrhythmia in COVID-19 patients. Furthermore, ivermectin
326 significantly reduced FPD_c in Nsp8^{OE} and M^{OE} CMs (Figure 7J), whereas no significant
327 effect of meclizine on FPD_c was observed (Figure 7K).

328

329 **Discussion**

330 Understanding the cardiac manifestations in patients with SARS-CoV-2 infection is critical
331 for health care of acute and post-acute COVID-19 patients (39,40). In this study, we reveal
332 the genome-wide responses of host hPSC-CMs to SARS-CoV-2 viral genes Nsp6, Nsp8
333 and M in whole transcriptome and interactome. Our findings uncover the compromised
334 cellular ATP level of hPSC-CMs which overexpress Nsp6, Nsp8 or M. FDA-approved
335 drugs, ivermectin and meclizine, could sustain the cellular ATP level to attenuate
336 apoptosis and dysfunctions of hPSC-CMs upon Nsp6, Nsp8 or M overexpression. Our
337 results suggest that the impaired ATP hemostasis might play a vital role in SARS-CoV-2
338 gene-induced CM injury in the heart, and possibly in other organs/tissues that are targets

339 of SARS-CoV-2 as well. Notably, although both Nsp6^{OE}, Nsp8^{OE} and M^{OE} and SARS-
340 CoV-2 infection led to concordant transcriptomic changes of hPSC-CMs (Figures 3B-C),
341 ~70% DEGs were solely induced by SARS-CoV-2 virus (Figure 3G-H), suggesting that
342 the other SARS-CoV-2 genes might also affect the transcriptome of host human CMs via
343 different targets or under different mechanisms. Since the unique pathways induced by
344 SARS-CoV-2 virus were related to apoptosis, gene transcription and multiple metabolic
345 processes, these results imply that at least some of other SARS-CoV-2 genes might also
346 contribute to CM injury and affect the metabolism of host human CMs.

347

348 Multiple clinical studies reported that myocardial dysfunctions and injuries were
349 commonly found in COVID-19 patients, and positively contributed to the overall mortality
350 (3-5,22,41). Recently, Bailey et al.(9) reported that SARS-CoV-2 can directly and
351 specifically infect CMs within the hearts of COVID-19 patients. Myocardial tissues from 4
352 autopsy of COVID-19 patients with clinical myocarditis were examined. In all autopsies,
353 CM infection was identified by intramyocyte expressions of viral RNA and protein, and
354 macrophage infiltration associated with areas of myocyte cell death. This study provided
355 direct evidence for CM infection in the COVID-19 patient hearts. Additionally, several
356 research groups reported that SARS-CoV-2 virus could infect human ESC/iPSC-derived
357 CMs, and induce apoptosis (15,16), sarcomere fragmentations (17) and electrical and
358 mechanical dysfunctions (18) compared with mock control. After infection, the
359 intramyocyte viral particles were observed by using transmission electron microscopy. All
360 these studies indicate that hPSC-CMs could be utilized as an *in vitro* model for conducting
361 mechanistic studies of SARS-CoV-2 viral genes in human CMs. In this study, we identified

362 the susceptibility of hPSC-CMs to individual SARS-CoV-2 genes. Nsp6 and Nsp8 are the
363 non-structural proteins of SARS-CoV-2. M is the structural protein of SARS-CoV-2, which
364 is the most abundant structural protein in the virus particle. The mechanisms of CM death
365 induced by those genes have not been previously described. Interestingly, we found that
366 enforced expression of Nsp6, Nsp8 or M was sufficient to induce apoptosis and
367 dysfunction of hPSC-CMs (Figures 4 and 7A,B,E), which phenocopied SARS-CoV-2
368 infected hPSC-CMs from other reports (9,15,17,42). Whole mRNA-seq revealed global
369 transcriptional changes of Nsp6^{OE}, Nsp8^{OE} and M^{OE} hESC-CMs compared to control
370 hESC-CMs (Figures 2C-E), particularly with differentially expressed genes enriched into
371 activated cellular injury and immune responses whereas reduced calcium/gap junction
372 signaling (Figure 3H). Notably, these global transcriptome changes are consistent with
373 the previous published whole mRNA-seq results from SARS-CoV-2 virus directly infected
374 hPSC-CMs (9). These results thus indicate that expression of the exogenous SARS-CoV-
375 2 viral genes could profoundly disrupt the gene expression programs of human CMs,
376 which might subsequently cause CM abnormalities in COVID-19 patients.

377

378 The interactions of SARS-CoV-2 viral genes with host cell proteins also play a critical role
379 in CM abnormalities. In this study, by studying the interactome of Nsp6, Nsp8 or M within
380 hESC-CMs, we found that they all interacted with ATPase subunits and compromised the
381 cellular ATP level in hPSC-CMs (Figures 5A,K). Bailey et al. also found downregulated
382 ATP metabolic process in SARS-CoV-2 infected hPSC-CMs compared to control using
383 whole mRNA-seq (9). Therefore, our findings suggest a possible central role of ATP
384 homeostasis in SARS-CoV-2-induced tissue injuries in CMs, and highly likely in other

385 SARS-CoV-2 vulnerable tissue cells in lung or kidney, although the mechanisms how
386 Nsp6, Nsp8 or M could hijack ATPase remain to be elucidated.

387

388 Due to the consistent contractions, heart muscle cells consume a large amount of energy,
389 which makes CMs one of the most vulnerable cell types to insufficient ATP supply.
390 Therefore, we explored the pharmaceutical strategies to enhance cellular ATP levels, and
391 found two FDA-approved drugs ivermectin and meclizine significantly reduced SARS-
392 CoV-2 genes-induced cell death and electrical dysfunctions in human CMs. Ivermectin
393 belongs to the group of avermectins (AVM), which is a series of 16-membered
394 macrocyclic lactone compounds discovered in 1967. FDA approved it for human use in
395 1987. Although ivermectin is used for treating parasitic infection, it was identified as a
396 mitochondrial ATP protector in CMs and increased mitochondrial ATP production in
397 human CMs (33), which was verified in our study as well. Interestingly, a study reported
398 that ivermectin was an inhibitor of SARS-CoV-2 *in vitro*, and a single treatment for 48 hrs.
399 led to ~5000-fold reduction of virus in cell culture (34). Notably, a recent clinical study
400 reported that administration of ivermectin was associated with significantly lower mortality
401 in hospitalized COVID-19 patients(43), although it is unclear whether ivermectin could
402 reduce mortality via preserving ATP levels in SARS-CoV-2 vulnerable heart muscle
403 and/or other tissue cells. Meclizine, an over-the-counter anti-nausea and -dizziness drug,
404 was identified via a 'nutrient-sensitized' chemical screen. Meclizine is primarily used as
405 an antihistamine. However, it has been reported that meclizine had cardio-protection
406 effect through promoting glycolysis of CMs (35), which increased ATP synthesis. Other
407 study also reported that meclizine stimulated glycolysis, mitigated ATP depletion and

408 protected mitochondria function (44). Those studies support our findings that meclizine
409 might increase ATP level to mitigate SARS-CoV-2 gene-induced cell death of hPSC-CMs.
410 Currently, whether administration of meclizine is associated with reduced mortality in
411 hospitalized COVID-19 patients is still unknown and requires further clinical investigations.

412

413 **Funding**

414 This work was supported by Startup to L.Y., and 2020 IUSM Center for Computational
415 Biology and Bioinformatics Pilot Award to L.Y and J. W.

416

417 **Acknowledgements**

418 We thank the Proteomics Core of Indiana University School of Medicine (IUSM) for Co-
419 IP-MS. Work in the IUSM Proteomics Core was supported, in part, with support from the
420 Indiana Clinical and Translational Sciences Institute, which is funded by the
421 UL1TR002529 from the National Institutes of Health, National Center for Advancing
422 Translational Sciences, Clinical and Translational Sciences Award. Acquisition of the
423 IUSM Proteomics core instrumentation used for this project, the Orbitrap Fusion Lumos,
424 was provided by the Indiana University Precision Health Initiative. We also thank Indiana
425 Center for Biological Microscopy of Indiana University School of Medicine (IUSM) for cell
426 imaging.

427

428 **Author contributions**

429 JL and LY initiated and designed studies. JL performed all experiments and data analyses.
430 SW, LH, CW, ES, YW and YLL assisted in whole RNA-seq. YZ and JW assisted in
431 bioinformatics. YL, WS and ML supported calcium handling and MEA experiments and
432 data analyses. JL, JW, ML and LY wrote the manuscript.

433

434 **Declaration of interest**

435 The authors declare no competing interests.

436

437

438 **References**

- 439 1. Zhu N, Zhang D, Wang W et al. A Novel Coronavirus from Patients with Pneumonia in China,
440 2019. *N Engl J Med* 2020;382:727-733.
- 441 2. Zhou P, Yang XL, Wang XG et al. A pneumonia outbreak associated with a new coronavirus of
442 probable bat origin. *Nature* 2020;579:270-273.
- 443 3. Guo T, Fan Y, Chen M et al. Cardiovascular Implications of Fatal Outcomes of Patients With
444 Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020;5:811-818.
- 445 4. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in
446 Wuhan, China. *Lancet* 2020;395:497-506.
- 447 5. Shi S, Qin M, Shen B et al. Association of Cardiac Injury With Mortality in Hospitalized Patients
448 With COVID-19 in Wuhan, China. *JAMA Cardiol* 2020;5:802-810.
- 449 6. Dhakal BP, Sweitzer NK, Indik JH, Acharya D, William P. SARS-CoV-2 Infection and Cardiovascular
450 Disease: COVID-19 Heart. *Heart Lung Circ* 2020;29:973-987.
- 451 7. Clerkin KJ, Fried JA, Raikhelkar J et al. COVID-19 and Cardiovascular Disease. *Circulation*
452 2020;141:1648-1655.
- 453 8. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic
454 mechanisms to clinical perspectives. *Nat Rev Cardiol* 2020;17:543-558.
- 455 9. Bailey AL, Dmytrenko O, Greenberg L et al. SARS-CoV-2 Infects Human Engineered Heart Tissues
456 and Models COVID-19 Myocarditis. *J Am Coll Cardiol Basic Trans Science* 2021;6:331-345.
- 457 10. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and
458 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020;181:271-280 e8.
- 459 11. Shang J, Wan Y, Luo C et al. Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A*
460 2020;117:11727-11734.
- 461 12. Zang R, Gomez Castro MF, McCune BT et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2
462 infection of human small intestinal enterocytes. *Sci Immunol* 2020;5.
- 463 13. Hikmet F, Mear L, Edvinsson A, Micke P, Uhlen M, Lindskog C. The protein expression profile of
464 ACE2 in human tissues. *Mol Syst Biol* 2020;16:e9610.

- 465 14. Yang L, Han Y, Nilsson-Payant BE et al. A Human Pluripotent Stem Cell-based Platform to Study
466 SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. *Cell Stem Cell*
467 2020;27:125-136 e7.
- 468 15. Sharma A, Garcia G, Jr., Wang Y et al. Human iPSC-Derived Cardiomyocytes Are Susceptible to
469 SARS-CoV-2 Infection. *Cell Rep Med* 2020;1:100052.
- 470 16. Bojkova D, Wagner JUG, Shumliakivska M et al. SARS-CoV-2 infects and induces cytotoxic effects
471 in human cardiomyocytes. *Cardiovasc Res* 2020.
- 472 17. Perez-Bermejo JA, Kang S, Rockwood SJ et al. SARS-CoV-2 infection of human iPSC-derived
473 cardiac cells predicts novel cytopathic features in hearts of COVID-19 patients. *bioRxiv* 2020.
- 474 18. Marchiano S, Hsiang TY, Khanna A et al. SARS-CoV-2 Infects Human Pluripotent Stem Cell-
475 Derived Cardiomyocytes, Impairing Electrical and Mechanical Function. *Stem Cell Reports*
476 2021;16:478-492.
- 477 19. Ludwig TE, Bergendahl V, Levenstein ME, Yu J, Probasco MD, Thomson JA. Feeder-independent
478 culture of human embryonic stem cells. *Nat Methods* 2006;3:637-46.
- 479 20. Ludwig TE, Levenstein ME, Jones JM et al. Derivation of human embryonic stem cells in defined
480 conditions. *Nat Biotechnol* 2006;24:185-7.
- 481 21. Lian X, Zhang J, Azarin SM et al. Directed cardiomyocyte differentiation from human pluripotent
482 stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. *Nat Protoc*
483 2013;8:162-75.
- 484 22. Shi S, Qin M, Yang B. Coronavirus Disease 2019 (COVID-19) and Cardiac Injury-Reply. *JAMA*
485 *Cardiol* 2020.
- 486 23. Gordon DE, Jang GM, Bouhaddou M et al. A SARS-CoV-2 protein interaction map reveals targets
487 for drug repurposing. *Nature* 2020;583:459-468.
- 488 24. Liu J, Liu S, Gao H et al. Genome-wide studies reveal the essential and opposite roles of ARID1A
489 in controlling human cardiogenesis and neurogenesis from pluripotent stem cells. *Genome Biol*
490 2020;21:169.
- 491 25. Tohyama S, Hattori F, Sano M et al. Distinct metabolic flow enables large-scale purification of
492 mouse and human pluripotent stem cell-derived cardiomyocytes. *Cell Stem Cell* 2013;12:127-37.
- 493 26. Liu J, Li Y, Lin B, Sheng Y, Yang L. HBL1 Is a Human Long Noncoding RNA that Modulates
494 Cardiomyocyte Development from Pluripotent Stem Cells by Counteracting MIR1. *Dev Cell*
495 2017;43:372.
- 496 27. Yang L, Soonpaa MH, Adler ED et al. Human cardiovascular progenitor cells develop from a KDR+
497 embryonic-stem-cell-derived population. *Nature* 2008;453:524-8.
- 498 28. Banerjee AK, Blanco MR, Bruce EA et al. SARS-CoV-2 Disrupts Splicing, Translation, and Protein
499 Trafficking to Suppress Host Defenses. *Cell* 2020.
- 500 29. Eguchi Y, Shimizu S, Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis
501 or necrosis. *Cancer Res* 1997;57:1835-40.
- 502 30. Tatsumi T, Shiraishi J, Keira N et al. Intracellular ATP is required for mitochondrial apoptotic
503 pathways in isolated hypoxic rat cardiac myocytes. *Cardiovasc Res* 2003;59:428-40.
- 504 31. Tsujimoto Y. Apoptosis and necrosis: intracellular ATP level as a determinant for cell death
505 modes. *Cell Death Differ* 1997;4:429-34.
- 506 32. Miyoshi N, Oubrahim H, Chock PB, Stadtman ER. Age-dependent cell death and the role of ATP
507 in hydrogen peroxide-induced apoptosis and necrosis. *Proc Natl Acad Sci U S A* 2006;103:1727-
508 31.
- 509 33. Nagai H, Satomi T, Abiru A et al. Antihypertrophic Effects of Small Molecules that Maintain
510 Mitochondrial ATP Levels Under Hypoxia. *EBioMedicine* 2017;24:147-158.
- 511 34. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits
512 the replication of SARS-CoV-2 in vitro. *Antiviral Res* 2020;178:104787.

- 513 35. Gohil VM, Sheth SA, Nilsson R et al. Nutrient-sensitized screening for drugs that shift energy
514 metabolism from mitochondrial respiration to glycolysis. *Nat Biotechnol* 2010;28:249-55.
515 36. Fearnley CJ, Roderick HL, Bootman MD. Calcium signaling in cardiac myocytes. *Cold Spring Harb*
516 *Perspect Biol* 2011;3:a004242.
517 37. Bers DM. Calcium cycling and signaling in cardiac myocytes. *Annu Rev Physiol* 2008;70:23-49.
518 38. Bers DM, Guo T. Calcium signaling in cardiac ventricular myocytes. *Ann N Y Acad Sci*
519 2005;1047:86-98.
520 39. Medigeshi GR, Hirsch AJ, Streblov DN, Nikolich-Zugich J, Nelson JA. West Nile virus entry
521 requires cholesterol-rich membrane microdomains and is independent of alphavbeta3 integrin. *J*
522 *Virol* 2008;82:5212-9.
523 40. Brinton MA. Replication cycle and molecular biology of the West Nile virus. *Viruses* 2013;6:13-
524 53.
525 41. Knight DS, Kotecha T, Razvi Y et al. COVID-19: Myocardial Injury in Survivors. *Circulation*
526 2020;142:1120-1122.
527 42. Bailey AL, Dmytrenko O, Greenberg L et al. SARS-CoV-2 Infects Human Engineered Heart Tissues
528 and Models COVID-19 Myocarditis. *J Am Coll Cardiol Basic Transl Science* 2021.
529 43. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is Associated With
530 Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The ICON Study. *Chest*
531 2020.
532 44. Zhuo M, Gorgun MF, Englander EW. Augmentation of glycolytic metabolism by meclizine is
533 indispensable for protection of dorsal root ganglion neurons from hypoxia-induced
534 mitochondrial compromise. *Free Radic Biol Med* 2016;99:20-31.

535

536

537 **Figure legends:**

538 **Figure 1. Prediction of SARS-CoV-2 viral genes affecting human cardiomyocytes**
539 **and confirmation of infection by SARS-CoV-2 spike pseudotyped lentivirus.**

540 **(A)** Coding genes annotation of the SARS-CoV-2 genome.

541 **(B)** Strategies to predict SARS-CoV-2 genes potentially affecting functions of human
542 cardiomyocytes. The double-headed arrows indicate the potential interactions between
543 SARS-CoV-2 proteins and essential proteins in human cardiomyocytes.

544 **(C)** Stable hPSC cell lines were established to study the functions of SARS-CoV-2 genes
545 in human CMs. OE, overexpression.

546 **(D)** RT-qPCR detection of SARS-CoV-2 virus receptor genes ACE2, TMPRSS2,
547 TMPRSS4 and the cardiomyocyte marker CTNT during cardiac differentiation from
548 human ESCs. RNA samples were collected every 2 days from day 0 to day 10 of
549 differentiation. Beating cardiomyocytes were observed at day 7. All dots are shown as
550 mean \pm SD. (n=3).

551 **(E)** Gene expression profiles of SARS-CoV-2 viral receptor genes ACE2, TMPRSS2/3,
552 and cardiomyocyte markers NKX2-5, MYH6, CTNT in hESC-derived cardiomyocytes
553 based on our scRNA-seq data³³.

554 **(F)** Flow cytometry analysis of GFP⁺ cells in hESC-CMs after infection with SARS-CoV-2
555 Spike pseudotyped lentivirus with GFP reporter. After 48 hours of infection, flow cytometry
556 was performed to detect GFP⁺ cells. Cells without virus infection were the blank control
557 cells. All bars are shown as mean \pm SD. (n=3). A two-tailed unpaired *t*-test was used to
558 calculate *P*-values: **P* < 0.05 (vs. no virus).

559

560 **Figure 2. Whole mRNA-seq reveals the impact of SARS-CoV-2 viral genes on the**
561 **transcriptome of hESC-derived cardiomyocytes.**

562 **(A)** RT-PCR detection of SARS-CoV-2 genes Nsp6, Nsp8 and M in the stable
563 overexpression (OE) H9 hESC lines.

564 **(B)** The scheme of whole mRNA-seq to globally study the impact of SARS-CoV-2 viral
565 genes on purified hESC-CMs.

566 **(C-E)** Volcano blots showing differential expressed genes caused by Nsp6^{OE} **(C)**, Nsp8
567 ^{OE} **(D)** and M^{OE} **(E)** in hESC-CMs.

568 **(F)** Global view of transcriptomic changes induced by Nsp6^{OE}, Nsp8^{OE} and M^{OE} in hESC-
569 CMs.

570 **(G)** Gene ontology (GO) analyses of the upregulated genes induced by Nsp6^{OE}, Nsp8^{OE}
571 and M^{OE} in hESC-CMs.

572 **(H-I)** Canonical signaling pathways analyses of the upregulated genes induced by Nsp6^{OE},
573 Nsp8^{OE} and M^{OE} in hESC-CMs.

574 **(J)** Canonical signaling pathways analyses of the downregulated genes induced by
575 Nsp6^{OE}, Nsp8^{OE} and M^{OE} in hESC-CMs.

576

577

578 **Figure 3. Whole mRNA-seq reveals SARS-CoV-2 viral genes-induced cell death and**
579 **dysfunctions in hESC-derived cardiomyocytes**

580 **(A)** Volcano blots showing differential expressed genes in hiPSCs (SARS-CoV-2 vs.
581 Mock).

582 **(B-C)** Comparison of DEGs between hESC-CMs (Nsp6^{OE}, Nsp8^{OE} and M^{OE} vs. Control)
583 and hiPSCs (SARS-CoV-2 vs. Mock). The fold enrichment (F.E.) around 2 with
584 remarkable *p*-value indicates the significant overlap between two gene sets.

585 Heat map analyses of apoptotic genes in **(D)**, inflammation genes in **(E)**, and heart
586 contraction genes in **(F)**.

587 **(G)** Frequencies of SARS-CoV-2 infection up-regulated DEGs identified in Nsp6^{OE}/
588 Nsp6^{OE}/M^{OE} or not.

589 **(H)** Frequencies of SARS-CoV-2 infection down-regulated DEGs identified in Nsp6^{OE}/
590 Nsp6^{OE}/M^{OE} or not.

591 **(I)** GO analysis of DEGs solely up-regulated by SARS-CoV-2 infection.

592 **(J)** GO analysis of DEGs solely down-regulated by SARS-CoV-2 infection.

593 All bars are shown as mean \pm SD. (n=3). A two-tailed unpaired *t*-test was used to calculate
594 *P*-values: **P* < 0.05 (vs. Control).

595

596 **Figure 4. Overexpression of SARS-CoV-2 genes induces cell death of hPSCs-**
597 **derived cardiomyocytes.**

598 **(A)** The scheme cardiomyocytes differentiation from hESCs in 2D monolayer condition,
599 followed with apoptosis assessments.

600 **(B-C)** Flow cytometry analysis of the ratios of TUNEL⁺ cells in hESCs-derived
601 cardiomyocytes (CTNT⁺). (C) All bars are shown as mean \pm SD. (n=4). A two-tailed
602 unpaired *t*-test was used to calculate *P*-values: **P* < 0.05 (vs. Control).

603 **(D)** Representative immunostaining images of TUNEL⁺ and CTNT⁺ cells in hESCs-
604 derived cardiomyocytes with overexpression of SARS-CoV-2 genes. Scale bar, 100 μ m.

605 **(E)** Statistical data analysis of immunostaining results from **(D)**. All bars are shown as
606 mean \pm SD. (n=3). A two-tailed unpaired *t*-test was used to calculate *P*-values: **P* < 0.05
607 (vs. Control).

608 **(F-G)** Flow cytometry analysis of apoptotic cells in hESC-derived cardiomyocytes using
609 Annexin-V-PI double staining. All bars are shown as mean \pm SD. (n=3). A two-tailed
610 unpaired *t*-test was used to calculate *P*-values: **P* < 0.05 (vs. Control).

611 **(H)** The scheme cardiomyocytes differentiation from hiPSCs in 3D Embryoid Body (EB)
612 condition, followed with apoptosis assessments.

613 **(I-J)** Flow cytometry analysis of TUNEL⁺ cells in the CM (CTNT⁺) population of hiPSCs-
614 derived EBs. All bars are shown as mean \pm SD. (n=4). A two-tailed unpaired *t*-test was
615 used to calculate *P*-values: **P* < 0.05 (vs. Control).

616 **(K)** Representative immunostaining images of TUNEL⁺ cells in hiPSCs-derived EBs
617 containing CTNT⁺ CMs. Scale bar, 100 μ m.

618 **(L)** Statistical data analysis of immunostaining results from **(K)**. All bars are shown as
619 mean \pm SD. (n=3). A two-tailed unpaired *t*-test was used to calculate *P*-values: **P* < 0.05
620 (vs. Control).

621 **(M-N)** Western blotting detection of CASP3, cleaved CASP3, CASP9 and cleaved CASP9
622 protein expression in hiPSC-CMs **(M)** and hESC-CMs **(N)**.

623

624 **Figure 5. SARS-CoV-2 genes interact with host proteins in hPSC-CMs and reduce**
625 **cellular ATP level.**

626 **(A)** The scheme of Co-IP MS method to globally study SARS-CoV-2 protein interactors
627 in human cardiomyocytes.

628 **(B-D)** Gene Ontology (GO) analyses of Nsp6 interactors (**B**), Nsp8 interactors (**C**) and M
629 interactors (**D**).

630 **(E-G)** Signaling pathways (SP) analyses of Nsp6 interactors (**E**), Nsp8 interactors (**F**) and
631 M interactors (**G**).

632 **(H)** Protein-protein interaction (PPI) shows Nsp6 interactors are associated with cardiac
633 hypertrophy and mitochondrial dysfunction.

634 **(I)** Protein-protein interaction (PPI) shows Nsp8 interactors are associated with cardiac
635 hypertrophy, mitochondrial dysfunction and cardiac arrhythmia.

636 **(J)** Protein-protein interaction (PPI) show M interactors are associated with cardiac
637 hypertrophy, mitochondrial dysfunction and cardiac arrhythmia.

638 **(K)** Protein-protein interaction (PPI) reveals the ATPase subunits ATP5A1 and ATP5B
639 are shared interactors by Nsp6/Nsp8/M proteins in hPSC-CMs.

640 **(L)** Co-IP Western-blotting verification of the interactions of ATP5A1/ATP5B and
641 Nsp6/Nsp8/M proteins in hESC-CMs.

642 **(M)** ATP level detection in hESCs-derived cardiomyocytes. All bars are shown as mean
643 \pm SD. (n=3). A two-tailed unpaired *t*-test was used to calculate *P*-values: **P* < 0.05 (vs.
644 Control).

645 **(N)** ATP level detection in hiPSCs-derived cardiomyocytes. All bars are shown as mean
646 \pm SD. (n=3). A two-tailed unpaired *t*-test was used to calculate *P*-values: **P* < 0.05 (vs.
647 Control).

648

649 **Figure 6. FDA-approved drugs can ameliorate SARS-CoV-2 genes-induced cell**
650 **death through restoring cellular ATP level.**

651 **(A)** ATP level detection in hESC-derived CMs. Ivermectin final concentration is 0.5 μ M.
652 Meclizine final concentration is 0.5 μ M. Treatment time is 3 hours.

653 **(B-E)** Representative immunostaining images of TUNEL⁺ and CTNT⁺ CMs in control
654 hiPSC-derived EBs **(B)**, hiPSCs-derived EBs with Nsp6 overexpression (Nsp6^{OE}) **(C)**,
655 hiPSC-derived EBs with Nsp8 overexpression (Nsp8^{OE}) **(D)** and hiPSC-derived EBs with
656 M overexpression (M^{OE}) **(E)**. Ivermectin final concentration is 0.5 μ M. Meclizine final
657 concentration is 0.5 μ M. Treatment time is 2 days.

658 **(F)** Statistical data analysis of immunostaining results from **(B-E)**. All bars are shown as
659 mean \pm SD. (n=3). A two-tailed unpaired *t*-test was used to calculate *P*-values. **P* < 0.05
660 (vs. Control), #*P* < 0.05 (vs. Nsp6^{OE}), ***P* < 0.05 (vs. Nsp8^{OE}), ****P* < 0.05 (vs. M^{OE}).

661

662 **Figure 7. SARS-CoV-2 genes-induced abnormal calcium handling and electrical**
663 **dysfunction in human cardiomyocytes can be ameliorated by FDA-approved drugs.**

664 **(A)** Calcium handling analysis in control hESC-CMs. Y-axis represents intensity and X-
665 axis represents time (in second, s).

666 **(B)** Calcium handling analysis in Nsp6^{OE}, Nsp8^{OE} or M^{OE} hESC-CMs treated without or
667 with drugs for 1 hour. Y-axis means intensity. X-axis represents time (in second, s).

668 **(C)** Interspike interval (ISI) distribution analysis from **(A)**. Y-axis means beating frequency
669 in a specific time window. X-axis means time (in second, s).

670 **(D)** Interspike interval (ISI) distribution analysis from **(B)** in different CM cell lines treated
671 with or without drugs for 1 hour.

672 **(E)** Electrophysiology analysis by multi-electrode arrays (MEAs) in hESC-CMs.
673 Representative field potential recordings of spontaneous beating hESC-CMs. For drug
674 treatment assay, the final concentrations of ivermectin and meclizine were 0.5 μ M. The
675 data was acquired after 1 hour of drug treatment.

676 **(F)** An illustration of the field potential duration (FPD, ms) from hESC-CMs.

677 **(G)** Representative traces illustrate the field potential duration (FPD, ms) from control and
678 Nsp6^{OE}, Nsp8^{OE} and M^{OE} hESC-CMs, respectively (from left to right).

679 **(H)** Field potential duration (FPD) analysis of MEAs data in hESC-CMs. All bars are
680 shown as mean \pm SD. (n = 5). A two-tailed unpaired t-test was used to calculate *P*-values.
681 **P* < 0.05 (vs. Control).

682 **(I)** Corrected FPD analysis of MEA data in hESC-CMs. Quantification of field potential
683 duration (FPD) was corrected by beat rate (FPDc) in spontaneous experiments using the
684 Bazett formula. All bars are shown as mean \pm SD. (n= 5). A two-tailed unpaired t-test was
685 used to calculate *P*-values. **P* < 0.05 (vs. Control).

686 **(J)** Corrected FPD (FPDc) analyses of MEA data in hESC-CMs treated with ivermectin
687 for 1 hour. All ivermectin-induced FPDc were normalized to that of control without
688 ivermectin treatment. All bars are shown as mean \pm SD, (n=3). A two-tailed unpaired t-
689 test was used to calculate *P*-values. **P* < 0.05 (ivermectin vs. no drug).

690 **(K)** Corrected FPD (FPDc) analyses of MEA data in hESC-CMs treated with meclizine for
691 1 hour. All meclizine-induced FPDc were normalized to that of control without meclizine
692 treatment. All bars are shown as mean \pm SD, (n=3). A two-tailed unpaired t-test was used
693 to calculate P-values. * $P < 0.05$ (Meclizine vs. no drug).




Figure 2





Figure 3



bioRxiv preprint doi: <https://doi.org/10.1101/2022.01.23.471147>; this version posted January 23, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Figure 4




Figure 5







Figure 6





Supplementary Figure 1



Supplementary Figure 1. Expression of SARS-CoV-2 receptor genes in human heart.


(A) RNA expression level of ACE2 gene in adult human heart tissues from RNA-seq data (NCBI database).

(B) RNA expression level of TMPRSS2 gene in adult human heart tissues from RNA-seq data (NCBI database).

(C) RNA expression level of TMPRSS4 gene in adult human heart tissues from RNA-seq data (NCBI database).

(D) Representative images of control and Nsp6OE, Nsp8OE and MOE in hESC lines.

Supplementary Figure 2




Supplementary Figure 2. MRNA-seq reveals that SARS-CoV-2 genes induces cell injuries and dysfunction in hESC-CMs.

(A-C) Signaling pathways activated by Nsp6OE, Nsp8OE and MOE in hESC-CMs.


(D-F) GO Hierarchy activated by Nsp6OE, Nsp8OE and MOE in hESC-CMs.

Supplementary Figure 3


A Cleaved-CASP3⁺ in hESC-CMs



B



C



Supplementary Figure 3. Overexpression of SARS-CoV-2 genes can cause cell death in hPSC-CMs.

(A) Flow cytometry analysis of cleaved CASP3⁺ cells in hESCs-derived cardiomyocytes (CMs) with overexpression of SARS-CoV-2 genes. All bars are shown as mean \pm SD. (n=8). A two-tailed unpaired t-test was used to calculate P-values: *P < 0.05 (vs. Control).

(B) Immunofluorescence of cleaved CASP3⁺ and CTNT⁺ cells in hESC-CMs with overexpression of SARS-CoV-2 genes.

(C) Statistical data analysis of immunostaining from (B). All bars are shown as mean \pm SD. (n=3). A two-tailed unpaired t-test was used to calculate P-values: *P < 0.05 (vs. Control).

Supplemental Information

Materials and Methods

Human pluripotent stem cells culture and cardiomyocytes differentiation

Human embryonic stem cell (hESC) line H9 and human induced pluripotent stem cell (hiPSC) line S3 were cultured on Matrigel (BD Biosciences)-coated plates in mTesR1 medium^{1,2}. For cardiomyocyte differentiation, the monolayer differentiation method was used based on published protocol³ with minor modification. Briefly, differentiation was initiated by removing the mTeSR1 medium and adding RPMI1640/B27 (no insulin) medium with 6 μ M CHIR99021 from day 0 to day 1. Then cells were induced in only RPMI1640/B27 (no insulin) medium from day 1 to day 3, followed with induction in RPMI1640/B27 (no insulin) medium with 5 μ M XAV-939 from day 3 to day 5. After day 5, cells were maintained in RPMI1640/B27 (no insulin) medium without any chemicals. Beating cardiomyocytes could be observed after differentiation of 7 days. For embryoid body (EBs) differentiation (3D differentiation), hiPSCs were differentiated towards CMs using the previously established protocol^{4,5}. Briefly, cardiomyocyte differentiation was conducted with EBs formation. EBs were treated with StemPro-34 SFM (1X) medium (10639011, Gibco.) with the following conditions: days 0-1 with BMP4 (2.5 ng/ml); days 1-4 with BMP4 (10 ng/ml), FGF-2 (5 ng/ml) and Activin A (2 ng/ml); and days 4-20 with XAV939 (5 μ M), after day 4 the medium was changed every 4 days. Beating EBs could be observed at day 10-13 after differentiation. For drug treatment assay, all beating EBs were maintained in DMEM medium (no glucose, Gibco) with 10% FBS. Both of the final concentration of Ivermectin and Meclizine was 0.5 μ M (drugs were dissolved in DMSO). The treatment time for apoptosis assay was 2 days. All cytokines were from R&D Systems. All chemicals or drugs were from Sigma Aldrich.

Lentivirus production and cell transduction

The lentiviral vector pLVX-EF1alpha-IRES-Puro-2xStrep-SARS-CoV-2-GFP (Nsp6, Nsp8, M or Orf9c) was transfected into the HEK293T cells with packaging plasmids psPAX2 and pMD2.G (gifts from Dr. Guang Hu in NIH) using X-treme GENE 9 transfection reagent (Roche) according to the transfection manual. After transfection of 2 days, viral supernatant was collected and cellular debris was removed by syringe filtering (0.45 µm pore size; Millipore). H9 hESCs or S3 hiPSCs cultured in mTesR1 medium were incubated with virus media for 4h, followed with fresh mTesR1 medium culture for overnight. Same infection was repeated after 24 hr. Puromycin was added to select puromycin-resistant H9 hESCs or S3 hiPSCs clones after 48h virus infection.

RT-qPCR

RNAs were isolated by RNeasy Kit (Qiagen). CDNA synthesis was carried out using High-Capacity RNA-to-cDNA™ Kit (Applied Biosystems). RT-qPCR was performed on QuantStudio 6 and 7 Flex Real-Time PCR Systems with Fast SYBR Green Master Mix (Applied Biosystems) according to the manufacturer's instructions. The RT-qPCR analysis were normalized to internal control GAPDH or beta-ACTIN using $2^{-\Delta\Delta Ct}$ method⁶. RT-qPCR data were presented with mean ± S.D. from at least three independent experiments. For all primers' information, please see the Table S3 Oligonucleotides.

Western Blotting

Proteins were extracted by Complete™ Lysis-M EDTA-free kit (Roche, 04719964001).

Protein samples were mixed with NuPAGE™ LDS Sample Buffer (4X), boiled for 5 min at 95 °C, run on 4–15% Mini-PROTEAN TGX Gels (Bio-Rad), transferred to PVDF membrane by using Trans-Blot® Turbo™ Transfer System (Bio-Rad), blocked with 1X TBST buffer containing 10% not-fat milk, and incubated overnight at 4 °C with the corresponding primary antibodies with 5% BSA in 1X TBST buffer. Membranes were washed three times for 5 min each with 1X TBST buffer, and then incubated for 1 h at room temperature with horseradish-peroxidase-conjugated secondary antibodies in blocking solution with 5% BSA in 1X TBST buffer. Membranes were washed again three times for 5 min with 1X TBST before revealing them with ECL Western Blotting Substrate (Pierce) and ChemiDoc Imaging System (Bio-Rad).

Co-immunoprecipitation (Co-IP)

Cell proteins were extracted by Pierce™ Classic Magnetic IP/Co-IP Kit (Thermo Scientific, 88804) according to the manuals. Protein Co-immunoprecipitation (Co-IP) was performed by using Pierce™ Classic Magnetic IP/Co-IP Kit as well. Co-IP protein samples analysis were performed by using Western blotting or submitted to Proteomics Core Facility at the Indiana University School of Medicine (IUSM) for mass spectrometry analysis.

Flow cytometry

Flow cytometry was performed based on our previous protocol ⁷. Briefly, attached cells were harvested and dissociated by using 0.25% trypsin-EDTA at 37°C incubator for 10 min. The dissociated cells were fixed in 4% PFA (diluted with 16% Paraformaldehyde (formaldehyde) aqueous solution) at room temperature for 10 min and washed 3 times

with 1X PBS. Cells were incubated in 1X blocking PBS buffer (containing 2% goat serum or 5% BSA plus 0.1% saponin) with corresponding primary antibodies at 37°C for 1h, following with corresponding secondary antibodies staining at 37°C for 1 h. For TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) experiments, staining was carried out by using In Situ Cell Death Detection Kit, Fluorescein (11684795910 Roche) according to the manual. Flow cytometry analysis was performed on Attune NxT Flow Cytometer (Thermo Fisher Scientific). Data were analyzed by using FlowJo software (Treestar).

SARS-CoV-2 spike pseudovirus infection

The SARS-CoV-2 Spike Pseudotyped Lentivirus with GFP reporter (60 concentration, 60X) was purchased from Virongy (USA). HESCs were cultured in mTesR1 medium on 6-well plate coated with Matrigel. Cells were infected with 1X or 2X SARS-CoV-2 Spike Pseudotyped Lentivirus. After 48 hours of infection, flow cytometry was performed to detect GFP⁺ cells. Cells without virus infection were the blank control cells. Flow cytometry analysis was performed on Attune NxT Flow Cytometer (Thermo Fisher Scientific, USA). Data were analyzed by using FlowJo software (Treestar, USA).

Apoptosis assay of live cells

Live cells apoptosis analysis was performed using Annexin-V-FLUOS Staining Kit (11858 777001, Roche) according to the manual. Briefly, cells were harvested and dissociated by using 0.25% trypsin-EDTA at 37°C incubator for 10 min. Single cells were washed in 1X PBS, then resuspend and incubated in 100 µl of Annexin-V-FLUOS labeling solution

for 15 min at room temperature, followed with the analysis on BD LSRII cytometer (Becton Dickinson) or Attune NxT Flow Cytometer (Thermo Fisher Scientific). Data were analyzed by using FlowJo software (Treestar).

ATP detection assay

The level of ATP within the cells was measured by Luminescent ATP Detection Assay Kit (ab113849, Abcam) according to the manual. Briefly, flow cytometry or hemocytometer was used to adjust live cell number. Same cell number for each group was used for the ATP detection. Live cells were resuspended in 50 μ l detergent solution with 1200 rpm shaking on Eppendorf ThermoMixer C for 5 min at room temperature. Then 50 μ l substrate solution was added to the detergent solution with 1200 rpm shaking on Eppendorf ThermoMixer C for 5 min at room temperature. All solution was transferred to Nunc™ MicroWell™ 96-Well, (Nunclon Delta-Treated, Flat-Bottom Microplate, White Polystyrene Plate, Thermo Scientific, 136101), followed with luminescence detection on GloMax Discover Microplate Reader (GM3000, Promega). For drug treatment assay, both of the final concentration of Ivermectin and Meclizine was 0.5 μ M, the treatment time was 3h.

Intracellular calcium handling

Cardiomyocytes were attached on 12-well plate coated with Matrigel and loaded with X-Rhod-1 (X14210, Invitrogen) in DMEM medium (no glucose) with 10% FBS containing Pluronic F-127 (final concentration 0.02%, P2443, Sigma) for 15 min at 37 °C incubator. Videos were acquired at a rate of 50 frames per second using the All-in-One Fluorescence Microscope BZ-X800 (KEYENCE CORPORATION). For drug treatment assay, both of

the final concentration of Ivermectin and Meclizine were 0.5 μM (drugs were dissolved in DMSO). The calcium handling signaling was acquired after 1 hour of drug treatment. Videos were analyzed in ImageJ software using a custom script that calculated the temporal changes in calcium fluorescence intensity.

Multi-electrode arrays (MEAs) for cardiomyocytes

Electrophysiology experiments were performed for cardiomyocytes after day 30 differentiation. All experiments were performed in DMEM medium (no glucose, Gibco) with 10% FBS. Cardiomyocytes were attached on cytoview MEA 24-well white plate (M384-tMEA-24W-5, Axion Biosystems) coated with Matrigel. Electrophysiology data were acquired by the Maestro Edge MEA System (Axion Biosystems) with the integrated environment chamber controlling the heat at 37 degree and the CO_2 at 5%.

Immunofluorescence

For immunostaining of attached cells, cells were fixed with 4% PFA (diluted from 16% Paraformaldehyde aqueous solution) for 10 min at room temperature. After washing with 1X PBS, cells were blocked for 1 h with 1X PBS blocking buffer containing 2% goat serum (or 5% BSA) and 0.1% saponin. Staining with corresponding primary antibodies diluted with blocking buffer was performed at -4°C for overnight. Staining with secondary antibodies were performed on next day, following with nucleus staining with DAPI. For beating EBs immunostaining, live EBs were fixed with 4% PFA (diluted from 16% Paraformaldehyde aqueous solution) for 10 min at room temperature, followed with 15% sucrose solution at room temperature until all EBs sunk. Then EBs were embed in OCT

and cryosectioning was performed. The EBs immunostaining protocol was the same as that of attached cells. For TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) experiments, staining of attached cells or EBs sections were carried out using In Situ Cell Death Detection Kit, Fluorescein (11684795910 Roche) according to the manual. Leica DM6B image system was used for imaging.

Co-immunoprecipitation mass spectrometry (CoIP-MS)

Beads were submitted to the proteomics core where they were covered in 8 M Urea, 50 mM Tris-HCl, pH 8.5, reduced with 5 mM tris (2-carboxyethyl) phosphine hydrochloride (TCEP) at room temperature for 30 min and alkylated with 10 mM chloroacetamide (CAM) for 30 min in the dark at room temperature. Digestion was carried out using Trypsin/Lys-C Mass spec grade protease mix (Promega, V5072) at a 1:100 protease to substrate ratio, overnight at 37 °C. The reaction was quenched with 0.5 % formic acid prior to LC-MS. Samples were analyzed using a 5 cm trap column and 15 cm (2 µm particle size, 50 µm diameter) EasySpray (801A) column on an UltiMate 3000 HPLC and Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific). Solvent B was increased from 5%-28% over 155 min, to 35% over 5 min, to 65% over 10 min and back to 5% over 12 min (Solvent A: 95% water, 5% acetonitrile, 0.1% formic acid; Solvent B: 100% acetonitrile, 0.1% formic acid). A data dependent top 20 method acquisition method was used with MS scan range of 350-1600 m/z, resolution of 70,000, AGC target 3e6, maximum IT of 50 ms. MS2 settings of fixed first mass 100 m/z, normalized collision energy of 36, isolation window of 1.5 m/z, resolution of 35,000, target AGC of 1e5, and maximum IT of 250 ms. For dd

acquisition a minimum AGC of $2e3$ and charge exclusion of 1, and ≥ 7 were used.

Tandem mass tag-mass spectrometry (TMT-MS)

Cell and tissue preparation

Cells were lysed in 8 M urea, 50 mM Tris-HCl, pH 8.5. Samples were sonicated in a Bioruptor® sonication system from DiagenDE Inc. (30 sec/30 sec on/off cycles for 15 minutes, 4°C). Following centrifugation at 12,000 rpm for 15 minutes, protein concentrations were determined using a Bradford protein assay (cat. num. 5000002, Bio-Rad). Protein samples in equal amounts (30 μ g) were reduced with 5 mM TCEP and alkylated with 10 mM (CAM). Samples were diluted with 100 mM Tris-HCl to a final urea concentration of 2 M and digested overnight with Trypsin/Lys-C Mix Mass Spectrometry (1:100 protease : substrate ratio, cat. num. V5072, Promega).

Peptide purification and labeling

Peptides were desalted on 50 mg Sep-Pak® Vac (Waters Corporation) employing a vacuum manifold. After elution from the column in 70% acetonitrile (ACN) 0.1% formic acid (FA), peptides were dried by speed vacuum and resuspended in 24 μ L of 50 mM triethylammonium bicarbonate (TEAB). Peptide concentration was measured using Pierce Quantitative Colorimetric Peptide Assay Kit (cat. num. 23275, Thermo Fisher Scientific) to ensure that an equal amount of each sample was labeled. Samples were then Tandem Mass Tag (TMT) labeled with 0.2 mg of reagent resuspended in 20 μ L acetonitrile for two hours at room temperature (WT:127N, Nsp6:128N, Nsp8:129N, M:130N, Orf9c:131; cat. num. 90309, Thermo Fisher Scientific TMT10plex™ Isobaric

Label Reagent Set; lot no. UH285567 and 131C lot UD280157A). Labelling reactions were quenched with hydroxylamine at room temperature 15 minutes. Labelled peptides were then mixed and dried by speed vacuum.

High pH basic fractionation

The peptide mixture was resuspended in 0.1% TFA (trifluoroacetic acid) and fractionated on a Pierce™ High pH reversed-phase peptide fractionation spin column using vendor methodology (cat. num. 84868). Each fraction was dried by speed vacuum and resuspended in 30 µL 0.1% FA.

Nano-LC-MS/MS Analysis.

Nano-LC-MS/MS analyses were performed on an EASY-nLC™ HPLC system coupled to an Orbitrap Fusion™ Lumos™ mass spectrometer (Thermo Fisher Scientific). Half of each fraction was loaded onto a reversed phase PepMap™ RSLC C18 column with Easy-Spray tip at 400 nL/min (ES802A, 2 µm, 100 Å, 75 µm x 25 cm). Peptides were eluted from 4-33% B over 120 minutes, 33%-80% B over 5 mins, and dropping from 50-10%B over the final 4 min min (Mobile phases A: 0.1% FA, water; B: 0.1% FA, 80% Acetonitrile). Mass spectrometer settings include capillary temperature of 300 °C and ion spray voltage was kept at 1.9 kV. The mass spectrometer method was operated in positive ion mode with a 4 second cycle time data-dependent acquisition with advanced peak determination and Easy-IC on (internal calibrant). Precursor scans (m/z 375-1600) were done with an orbitrap resolution of 120000, 30% RF lens, 105 ms maximum inject time (IT), standard automatic gain control (AGC) target. MS2 filters included an intensity threshold of 2.5e-4,

charges states of 2 to 6, 70% precursor fit threshold, and 60 s dynamic exclusion with dependent scan being performed on only one charge state per precursor. Higher-energy collisional dissociation (HCD) MS2 scans were performed at 50k orbitrap resolution, fixed collision energy of 37%, 200% normalized AGC target, and dynamic maximum IT.

Data analysis

Resulting RAW files were analyzed in Proteome Discover 2.4 (Thermo Fisher Scientific) with FASTA databases including Swiss-Prot UniProt Homo sapiens sequences (downloaded 09/17/2019) plus common contaminants. SEQUEST HT searches were conducted with a maximum number of 2 missed cleavages; precursor mass tolerance of 10 ppm; and a fragment mass tolerance of 0.02 Da. Static modifications used for the search were, 1) carbamidomethylation on cysteine (C) residues; 2) TMT sixplex label on lysine (K) residues and the N-termini of peptides (for TMT quant samples only). Dynamic modifications used for the search were oxidation of M, phosphorylation on S, T, Y, and acetylation of N-termini. IP-MS Sequest results were imported into Scaffold (Proteome Software) for Fishers exact test comparison. TMT quantification methods utilized isotopic impurity levels available from Thermo Fisher. Percolator False Discovery Rate was set to a strict setting of 0.01 and a relaxed setting of 0.05. Values from both unique and razor peptides were used for quantification. In the consensus workflow, peptides were normalized by total peptide amount with no scaling. Resulting abundance values for each sample, and abundance ratio values from Proteome Discoverer™ were exported to Microsoft Excel and are available in a supplemental file.

mRNA-seq

KAPA mRNA HyperPrep methods for mRNA sequencing

Total RNA will be first evaluated for its quantity, and quality, using Agilent Bioanalyzer 2100. For RNA quality, a RIN number of 7 or higher is desired. One hundred nanograms of total RNA will be used. cDNA library preparation includes mRNA purification/enrichment, RNA fragmentation, cDNA synthesis, ligation of index adaptors, and amplification, following the KAPA mRNA Hyper Prep Kit Technical Data Sheet, KR1352 – v4.17 (Roche Corporate). Each resulting indexed library will be quantified and its quality accessed by Qubit and Agilent Bioanalyzer, and multiple libraries pooled in equal molarity. The pooled libraries will then be denatured, and neutralized, before loading to NovaSeq 6000 sequencer at 300pM final concentration for 100b paired-end sequencing (Illumina, Inc.). Approximately 30-40M reads per library is generated. A Phred quality score (Q score) is used to measure the quality of sequencing. More than 90% of the sequencing reads reached Q30 (99.9% base call accuracy).

Data analysis

Quality control for raw mRNA-seq data was generated by FastQC v0.11.5 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Illumina adapter sequences and low-quality bases were trimmed by Trim Galore v0.4.5 (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/), followed by sequence mapping of high-quality paired-end reads to human genome (hg38) with the aligner STAR v2.7.2b⁸. We further used bam-filter in ngsutilsj v0.4.8 (<https://compgen.io/ngsutilsj>) to keep only properly and uniquely mapped paired reads (MAPQ \geq 10) for downstream analysis. FeatureCounts from package subread v1.6.5⁹ was employed to summarize

gene expression levels based on mapped reads according to GENECODE v31 annotation. Analysis of differential expression genes (DEGs) was performed by edgeR v3.32.1¹⁰, with read counts normalized by the trimmed mean of M-values (TMM) method after lowly expressed genes filtered out by the filterByExpr function using default settings. DEGs due to overexpression of SARS-CoV-2 viral coding genes were identified if their FDR-adjusted *p*-values were less than 0.05 based on the comparison between the viral gene overexpression and the control.

Functional enrichment analysis

The functional enrichment analysis of gene ontology (GO) biological process was carried out by using DAVID (<https://david.ncifcrf.gov/>), THE GENE ONTOLOGY RESOURCE (<http://geneontology.org/>) and Gorilla (<http://cbl-gorilla.cs.technion.ac.il/>). Canonical signaling pathway and toxicity analysis were performed on QIAGEN Ingenuity Pathway Analysis (IPA).

Protein-protein interaction (PPI) analysis

Protein-Protein Interaction Networks analysis were carried out on STRING software (<https://string-db.org/>).

Quantification and Statistical Analysis

Data comparisons between two groups (gene overexpression versus control) were conducted using an unpaired two-tailed *t*-test. All data were presented as mean \pm S.D. from at least three independent experiments. Differences with *P* values less than 0.05

were considered significant.

- 1 Ludwig, T. E. *et al.* Feeder-independent culture of human embryonic stem cells. *Nat Methods* **3**, 637-646, doi:10.1038/nmeth902 (2006).
- 2 Ludwig, T. E. *et al.* Derivation of human embryonic stem cells in defined conditions. *Nat Biotechnol* **24**, 185-187, doi:10.1038/nbt1177 (2006).
- 3 Lian, X. *et al.* Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. *Nat Protoc* **8**, 162-175, doi:10.1038/nprot.2012.150 (2013).
- 4 Yang, L. *et al.* Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. *Nature* **453**, 524-528, doi:10.1038/nature06894 (2008).
- 5 Lin, B. *et al.* High-purity enrichment of functional cardiovascular cells from human iPS cells. *Cardiovasc Res* **95**, 327-335, doi:10.1093/cvr/cvs185 (2012).
- 6 Peltier, H. J. & Latham, G. J. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. *RNA* **14**, 844-852, doi:10.1261/rna.939908 (2008).
- 7 Lu, T. Y. *et al.* Overexpression of microRNA-1 promotes cardiomyocyte commitment from human cardiovascular progenitors via suppressing WNT and FGF signaling pathways. *J Mol Cell Cardiol* **63**, 146-154, doi:10.1016/j.yjmcc.2013.07.019 (2013).
- 8 Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21, doi:10.1093/bioinformatics/bts635 (2013).
- 9 Liao, Y., Smyth, G. K. & Shi, W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. *Nucleic Acids Res* **47**, e47, doi:10.1093/nar/gkz114 (2019).
- 10 Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-140, doi:10.1093/bioinformatics/btp616 (2010).

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit IgG	Millipore	MAGNARIP01, RRID:AB_10681285
Mouse IgG	Millipore	MAGNARIP01, RRID:AB_2617156
Mouse IgG Isotype Control	R&D system	MAB002, RRID:AB_357344
Rabbit IgG	Cell Signaling Technology (CST)	#2729, RRID:AB_1031062

Alexa Fluor® 647 Mouse Anti-Cardiac Troponin T	BD Pharmingen	# 565744, RRID:AB_273934 1
Cardiac Troponin T antibody (mouse)	Thermo Fisher	MS-295-P, RRID:AB_61806
APC goat anti-mouse IgG	BD	550826, RRID:AB_398465
Strep Tag Monoclonal Antibody (GT661)	Thermo Fisher Scientific	# MA5-17283, RRID:AB_253874 9
Anti-Strep-tag II antibody	Abcam	ab76949, RRID:AB_152445 5
Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAb	Cell Signaling Technology (CST)	# 9664, RRID:AB_207004 2
Anti-CASP3 antibody	neomarkers	RB-1197-P0, RRID:AB_60471
Anti-GAPDH Mouse mAb (6C5)	Sigma-Aldrich	CB1001, RRID:AB_210742 6
Anti-cleaved CASP9 antibody (D315)	Cell Signaling Technology (CST)	9505P, RRID:AB_229072 7
Anti-CASP9 antibody	Cell Signaling Technology (CST)	9502P, RRID:AB_206862 1
Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 647	Invitrogen	A-21235, RRID:AB_253580 4
Goat anti-Rabbit IgG (H+L), Secondary Antibody, Alexa Fluor 488	Invitrogen	A27034, RRID:AB_253609 7
Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Cyanine5	Invitrogen	A10524, RRID:AB_253403 3
Anti-ATP5B antibody	Sigma-Aldrich	HPA001520
Anti-ATP5A1 (C-terminal) antibody	Sigma-Aldrich	SAB2700781
Chemicals, Peptides, and Recombinant Proteins		
RhBMP4	R&D system	314-BP
RhFGF2	R&D system	233-FB
RActivin A	R&D system	338-AC
XAV 939	R&D system	3748
Meclizine hydrochloride	Sigma-Aldrich	1377009
Ivermectin	Sigma-Aldrich	I8898
X-Rhod-1, AM, cell permeant	Invitrogen	X14210
Pluronic® F-127	Sigma-Aldrich	P2443
DreamTaq Green PCR Master Mix (2X)	Thermo Fisher Scientific	K1081

L-(+)-Lactic acid	Sigma-Aldrich	L1750
CHIR99021	R&D system	4423
Saponin	Sigma	S4521-25G
L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate	Sigma-Aldrich	A8960-5G
Puromycin dihydrochloride	Sigma-Aldrich	P8833-10MG
Polybrene	Sigma-Aldrich	H9268-5G
TrypLE™ Express Enzyme (1X), phenol red	Gibco	12605010
DAPI Fluoromount-G	southernbiotech	0100-20
UltraPure™ 0.5M EDTA, pH 8.0	Thermo Fisher Scientific	15575020
Fast SYBR Green Master Mix	Applied Biosystems	4385612
Critical Commercial Assays		
B-27™ Supplement, minus insulin	Thermo Fisher Scientific	A1895601
B-27™ Supplement (50X), serum free	Thermo Fisher Scientific	17504044
4–20% Mini-PROTEAN® TGX™ Precast Protein Gels (60X)	Bio-rad	4561096
The SARS-CoV-2 Spike Pseudotyped Lentivirus with GFP reporter	Virongy	CoV2-01
SuperSignal™ West Atto Ultimate Sensitivity Substrate	Thermo Fisher Scientific	A38555
In Situ Cell Death Detection Kit, TMR red	Roche	12156792910
Luminescent ATP Detection Assay Kit	abcam	ab113849
Annexin-V-FLUOS Staining Kit	Roche	11858777001
High-Capacity RNA-to-cDNA™ Kit	Applied Biosystems	4387406
Classic Magnetic IP/Co-IP Kit	Pierce	88804
RPMI 1640 Medium	Gibco	11875093
DMEM/F12	Gibco	11320082
DMEM, high glucose	Gibco	11965118
DMEM, no glucose	Gibco	11966025
StemPro™-34 SFM (1X)	Gibco	10639011
Pierce™ ECL Western Blotting Substrate	Pierce	32209
cOmplete™ Lysis-M EDTA-free	Roche	04719964001
RNeasy Mini Kit	Qiagen	74106

QIAquick Gel Extraction Kit Print	Qiagen	28706
QIAquick PCR Purification Kit Print	Qiagen	28106
Corning® Matrigel® Growth Factor Reduced (GFR) Basement Membrane Matrix, *LDEV-Free, 10mL	Corning	354230
Experimental Models: Cell Lines		
293T cells	ATCC	CRL-3216
Human iPSC line S3	Carvajal-Vergara et al., 2010	N/A
Human H9 hESCs	ATCC	HTB-176
Human S3 iPSCs with overexpression of SARS-CoV-2 gene Nsp6 Human S3 iPSCs with overexpression of SARS-CoV-2 gene Nsp8 Human S3 iPSCs with overexpression of SARS-CoV-2 gene M Human S3 iPSCs with overexpression of SARS-CoV-2 gene Orf9c Human S3 iPSCs with overexpression of EGFP	This paper	N/A
Human H9 hESCs with overexpression of SARS-CoV-2 gene Nsp6 Human H9 hESCs with overexpression of SARS-CoV-2 gene Nsp8 Human H9 hESCs with overexpression of SARS-CoV-2 gene M Human H9 hESCs with overexpression of SARS-CoV-2 gene Orf9c Human H9 hESCs with overexpression of EGFP Human H9 hESCs with overexpression of blank lentivirus backbone	This paper	N/A
Oligonucleotides		
Primers see Table S oligonucleotides	This paper	N/A
Recombinant DNA		
pLVX-EF1alpha-eGFP-2xStrep-IRES-Puro	Addgene	141395
pLVX-EF1alpha-SARS-CoV-2-nsp6-2xStrep-IRES-Puro	Addgene	141372
pLVX-EF1alpha-SARS-CoV-2-nsp8-2xStrep-IRES-Puro	Addgene	141374
pLVX-EF1alpha-SARS-CoV-2-M-2xStrep-IRES-Puro	Addgene	141386
pLVX-EF1alpha-2xStrep-SARS-CoV-2-orf9c-IRES-Puro	Addgene	141393
psPAX2	From Dr. Gang Hu lab (NIH)	N/A
pMD2.G	From Dr. Gang Hu lab (NIH)	N/A
Software and Algorithms		

Image J	National Institutes of Health	https://imagej.nih.gov/ij/
Loupe cell browser	10x Genomics	https://www.10xgenomics.com/cn/
Ingenuity Pathway Analysis (IPA)	QIAGEN	https://www.qiagen.com/us/products/discovery-and-translational-research/next-generation-sequencing/informatics-and-data/interpretation-content-databases/ingenuity-pathway-analysis/?clear=true#orderinginformation
GENE ONTOLOGY	THE GENE ONTOLOGY RESOURCE	http://geneontology.org/
CellRanger 2.1.0	10x Genomics	http://support.10xgenomics.com/
STRING	STRING CONSORTIUM	https://string-db.org
Adobe Illustrator	Adobe Inc.	https://www.adobe.com/products/illustrator.html
FlowJo (Treestar)	FlowJo, LLC	https://www.flowjo.com/about/company
Bacterial and viral strains		
MAX Efficiency™ DH5α Competent Cells	Invitrogen	18258012
One Shot™ Stbl3™ Chemically Competent E. coli	Invitrogen	C737303